Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) Short Interest Down 66.9% in March

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) saw a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 4,900 shares, a drop of 66.9% from the February 28th total of 14,800 shares. Based on an average daily trading volume, of 15,100 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.1% of the shares of the company are short sold.

Cryo-Cell International Price Performance

Shares of NYSEAMERICAN CCEL opened at $6.43 on Thursday. The firm has a market cap of $51.83 million, a PE ratio of -6.07 and a beta of 0.53. Cryo-Cell International has a 12 month low of $5.75 and a 12 month high of $9.50.

Cryo-Cell International Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, February 28th. Stockholders of record on Friday, February 14th were given a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 15.55%. The ex-dividend date of this dividend was Friday, February 14th. Cryo-Cell International’s dividend payout ratio (DPR) is -94.34%.

Wall Street Analyst Weigh In

Separately, Maxim Group dropped their price target on shares of Cryo-Cell International from $9.00 to $8.50 and set a “buy” rating on the stock in a research report on Tuesday, March 4th.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Northern Trust Corp raised its stake in shares of Cryo-Cell International by 78.2% during the 4th quarter. Northern Trust Corp now owns 38,902 shares of the company’s stock worth $288,000 after purchasing an additional 17,066 shares in the last quarter. Topline Capital Management LLC bought a new stake in Cryo-Cell International in the fourth quarter worth approximately $354,000. CreativeOne Wealth LLC acquired a new position in shares of Cryo-Cell International during the 4th quarter worth $113,000. Heron Bay Capital Management bought a new position in Cryo-Cell International during the fourth quarter valued at about $235,000. Finally, Rowlandmiller & PARTNERS.ADV bought a new position in shares of Cryo-Cell International in the 4th quarter valued at approximately $107,000. Institutional investors and hedge funds own 10.44% of the company’s stock.

About Cryo-Cell International

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.